image
Healthcare - Biotechnology - NASDAQ - US
$ 9.26
-2.11 %
$ 4.78 M
Market Cap
-0.01
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CERO stock under the worst case scenario is HIDDEN Compared to the current market price of 9.26 USD, CERo Therapeutics Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CERO stock under the base case scenario is HIDDEN Compared to the current market price of 9.26 USD, CERo Therapeutics Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one CERO stock under the best case scenario is HIDDEN Compared to the current market price of 9.26 USD, CERo Therapeutics Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CERO

image
$70.0$70.0$60.0$60.0$50.0$50.0$40.0$40.0$30.0$30.0$20.0$20.0$10.0$10.0$0.0$0.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
0 REVENUE
0.00%
-15.3 M OPERATING INCOME
-421.68%
-7.29 M NET INCOME
-287317.48%
-5.79 M OPERATING CASH FLOW
-0.00%
0 INVESTING CASH FLOW
100.00%
572 K FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-4.95 M OPERATING INCOME
-136.25%
-5.11 M NET INCOME
-387.36%
-4.45 M OPERATING CASH FLOW
-107.24%
0 INVESTING CASH FLOW
100.00%
6.32 M FINANCING CASH FLOW
168.89%
Balance Sheet CERo Therapeutics Holdings, Inc.
image
Current Assets 3.71 M
Cash & Short-Term Investments 3.33 M
Receivables 0
Other Current Assets 387 K
Non-Current Assets 2.49 M
Long-Term Investments 0
PP&E 1.99 M
Other Non-Current Assets 500 K
53.60 %6.23 %32.11 %8.06 %Total Assets$6.2m
Current Liabilities 7.4 M
Accounts Payable 4.51 M
Short-Term Debt 876 K
Other Current Liabilities 2.02 M
Non-Current Liabilities 699 K
Long-Term Debt 699 K
Other Non-Current Liabilities 0
55.64 %10.82 %24.92 %8.63 %Total Liabilities$8.1m
EFFICIENCY
Earnings Waterfall CERo Therapeutics Holdings, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 15.3 M
Operating Income -15.3 M
Other Expenses -8.01 M
Net Income -7.29 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)000(15m)(15m)8m(7m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
408.12% ROE
408.12%
-124.57% ROA
-124.57%
4795.56% ROIC
4795.56%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis CERo Therapeutics Holdings, Inc.
image
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)20222022Jul '22Jul '2220232023Jul '23Jul '2320242024Jul '24Jul '2420252025
Net Income -7.29 M
Depreciation & Amortization 1.16 M
Capital Expenditures -1
Stock-Based Compensation 96.9 K
Change in Working Capital 1.84 M
Others 1.82 M
Free Cash Flow -5.79 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets CERo Therapeutics Holdings, Inc.
image
CERO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership CERo Therapeutics Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
1.11 M USD 1
9-12 MONTHS
55.5 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial's Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly. globenewswire.com - 1 week ago
CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo's Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells. globenewswire.com - 2 weeks ago
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-twenty reverse stock split of the Company's common stock, par value $0.0001 per share (the “Common Stock”). globenewswire.com - 3 weeks ago
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has issued additional shares of its Series D Preferred Stock to certain institutional investors (the “Investors”) pursuant to the securities purchase agreement previously entered into by and between the Company and such Investors on April 22, 2025 with respect to the issuance of shares of Series D Preferred Stock for an aggregate purchase price of up to $8 million, including $5 million previously issued in April 2025 and up to $3 million issuable at the option of the Investors. The shares of Series D Preferred Stock are convertible into shares of the Company's common stock. globenewswire.com - 4 weeks ago
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236 Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic (i.e. globenewswire.com - 1 month ago
CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined evaluations SOUTH SAN FRANSCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the first patient in its Phase 1 clinical trial of CER-1236. globenewswire.com - 1 month ago
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million (the “Equity Rule”) globenewswire.com - 1 month ago
CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that TriStar Centennial Medical Center, through Sarah Cannon Research Institute (SCRI), in Nashville, Tennessee, is a clinical trial site for the Company's Phase 1 clinical of CER-1236. Collaborating with SCRI to advance cancer research, TriStar Centennial offers innovative clinical research trials for various disease indications. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway, with expected dosing of the first patient during the first half of 2025. globenewswire.com - 2 months ago
CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting SOUTH SAN FRANCISCO, Calif, April 25, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting a poster at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. globenewswire.com - 2 months ago
CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia SOUTH SAN FRANSCISCO, Calif, April 24, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado will be a key clinical trial site for the Company's Phase 1 clinical trial of CER-1236. Partnering with SCRI to advance cancer research, CBCI is the region's leader in blood cancer care and serves a seven-state region. The trial is focused on patients with acute myeloid leukemia (AML), and patient enrollment is underway with first dosing of the initial cohort of patients expected by June. globenewswire.com - 2 months ago
CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing SOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has entered into a securities purchase agreement for the issuance and sale of securities under a new convertible preferred stock transaction. globenewswire.com - 2 months ago
CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236 Results in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the allowance of two patent applications submitted to the U.S. Patent and Trademark Office (USPTO), which materially expands the Company's intellectual property portfolio. Patent Application No. globenewswire.com - 2 months ago
8. Profile Summary

CERo Therapeutics Holdings, Inc. CERO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 4.78 M
Dividend Yield 0.00%
Description CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.
Contact 201 Haskins Way, South San Francisco, CA, 94080 https://www.cero.bio
IPO Date Nov. 30, 2021
Employees 8
Officers Mr. Andrew Albert Kucharchuk M.B.A. Chief Financial Officer Dr. Kristen Pierce Ph.D. Chief Development Officer Dr. Lawrence Corey M.D. Co-founder & Head of Scientific Advisory Board Mr. Christopher B. Ehrlich M.B.A. Chief Executive Officer & Chair